GLP‐1 agonists represent an exciting new class of drugs with great potential to improve health outcomes for diabetes, weight loss management, and other health conditions, but are not without their own concerns regarding appropriateness for use, safety, and now quality and accessibility. This evidence concerns the gene GLP1R and diabetes mellitus.